295 related articles for article (PubMed ID: 20801411)
1. Pluripotent stem cell-derived natural killer cells for cancer therapy.
Knorr DA; Kaufman DS
Transl Res; 2010 Sep; 156(3):147-54. PubMed ID: 20801411
[TBL] [Abstract][Full Text] [Related]
2. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
Zhu H; Kaufman DS
Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
[TBL] [Abstract][Full Text] [Related]
3. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
Knorr DA; Ni Z; Hermanson D; Hexum MK; Bendzick L; Cooper LJ; Lee DA; Kaufman DS
Stem Cells Transl Med; 2013 Apr; 2(4):274-83. PubMed ID: 23515118
[TBL] [Abstract][Full Text] [Related]
4. Development of innate immune cells from human pluripotent stem cells.
Bernareggi D; Pouyanfard S; Kaufman DS
Exp Hematol; 2019 Mar; 71():13-23. PubMed ID: 30611869
[TBL] [Abstract][Full Text] [Related]
5. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
Zhu H; Kaufman DS
Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
[TBL] [Abstract][Full Text] [Related]
6. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
7. Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.
Zhu H; Lai YS; Li Y; Blum RH; Kaufman DS
Stem Cells; 2018 Feb; 36(2):134-145. PubMed ID: 29235195
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic and nature killer cell development from human pluripotent stem cells.
Ni Z; Knorr DA; Kaufman DS
Methods Mol Biol; 2013; 1029():33-41. PubMed ID: 23756940
[TBL] [Abstract][Full Text] [Related]
9. In vitro generation of immune cells from pluripotent stem cells.
Vandekerckhove B; Vanhee S; Van Coppernolle S; Snauwaert S; Velghe I; Taghon T; Leclercq G; Kerre T; Plum J
Front Biosci (Landmark Ed); 2011 Jan; 16(4):1488-504. PubMed ID: 21196243
[TBL] [Abstract][Full Text] [Related]
10. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells.
Kaufman DS
Blood; 2009 Oct; 114(17):3513-23. PubMed ID: 19652198
[TBL] [Abstract][Full Text] [Related]
11. Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells.
Martin CH; Woll PS; Ni Z; Zúñiga-Pflücker JC; Kaufman DS
Blood; 2008 Oct; 112(7):2730-7. PubMed ID: 18621931
[TBL] [Abstract][Full Text] [Related]
12. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
13. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
Nianias A; Themeli M
Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
[TBL] [Abstract][Full Text] [Related]
14. Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs).
Bock AM; Knorr D; Kaufman DS
J Vis Exp; 2013 Apr; (74):e50337. PubMed ID: 23644738
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
16. Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.
Ni Z; Knorr DA; Bendzick L; Allred J; Kaufman DS
Stem Cells; 2014 Apr; 32(4):1021-31. PubMed ID: 24307574
[TBL] [Abstract][Full Text] [Related]
17. Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective.
Jin G; Chang Y; Harris JD; Bao X
Cells Tissues Organs; 2023; 212(5):439-467. PubMed ID: 36599319
[TBL] [Abstract][Full Text] [Related]
18. Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms.
Ni Z; Knorr DA; Clouser CL; Hexum MK; Southern P; Mansky LM; Park IH; Kaufman DS
J Virol; 2011 Jan; 85(1):43-50. PubMed ID: 20962093
[TBL] [Abstract][Full Text] [Related]
19. Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy.
Knorr DA; Bock A; Brentjens RJ; Kaufman DS
Stem Cells Dev; 2013 Jul; 22(13):1861-9. PubMed ID: 23421330
[TBL] [Abstract][Full Text] [Related]
20. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
